Hovione has entered a co-promotion and collaboration agreement with Ligand to provide its customers with access to Ligand’s Captisol technology. Captisol, a chemically modified cyclodextrin, improves the solubility and stability of drugs and is currently used in six marketed products. The agreement allows Hovione to use Captisol technology in its solubilization programs, which include amorphous solid dispersions, crystal design and size reduction and control of particle size.
 
“Hovione is delighted to announce the ability to provide access to Captisol. There is no single solution to improving bioavailability and for a customer to access diverse options with a single supplier provides for greater probability of success and speedier outcomes,” said Dr. Colin Minchom, Hovione’s vice president of Particle Design.
 
“Hovione has manufactured Captisol for more than a decade, and we are very pleased to expand our partnership to help customers succeed. Providing for greater access to Captisol should efficiently enable the successful development of more poorly soluble molecules and further increase our Captisol partnership portfolio,” said Mr. Mathew W. Foehr, Ligand’s executive vice president and chief operating officer.